The chairman of the drug industry's main trade group in the U.S. said the group "hasn't withdrawn support" for the version of healthcare reform passed by the Senate, but that the Massachusetts election has "thrown everything up in the air a bit." David Brennan, chief executive of drug company AstraZeneca PLC and the current chairman of Pharmaceutical Research and Manufacturers of America, said "it's difficult to say right now" whether the industry's pledge to forgo $80 billion in revenue over a decade to help reduce healthcare costs will remain in place, the Wall Street Journal reports.
